PainReform (PainReform) ROE % Adjusted to Book Value : -266.34% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is PainReform ROE % Adjusted to Book Value?

PainReform's ROE % for the quarter that ended in Mar. 2024 was -484.74%. PainReform's PB Ratio for the quarter that ended in Mar. 2024 was 1.82. PainReform's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -266.34%.

PainReform ROE % Adjusted to Book Value Historical Data

The historical data trend for PainReform's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PainReform ROE % Adjusted to Book Value Chart

PainReform Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-31.23

-54.23

-151.05

-155.06

PainReform Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-111.71	-127.87	2.92	-373.33	-266.34

Competitive Comparison of PainReform's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, PainReform's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PainReform's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PainReform's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where PainReform's ROE % Adjusted to Book Value falls into.

PainReform ROE % Adjusted to Book Value Calculation

PainReform's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-102.34%	/	0.66
	=	-155.06%

PainReform's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-484.74%	/	1.82
	=	-266.34%

PainReform ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of PainReform's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

PainReform (PainReform) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PainReform Ltd (NAS:PRFX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Yigal Alon Street, Tel Aviv, ISR, 6744316

Website

https://www.painreform.com

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.